Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma (BRd)

August 23, 2016 updated by: PD Dr. Ulrich Mey, Cantonal Hospital of St. Gallen

An Open, Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Almost all patients with multiple myeloma who survive initial treatment will eventually relapse and require further therapy.

Background: Treatment with lenalidomide and dexamethasone has proven efficacy in two large randomized trials (MM-009 and MM-010) leading to a time to progression (TTP) of 17.1 months for patients with only one prior therapy and a TTP of 10.6 months for 2 and more prior therapies, respectively [1-3]. Continuous treatment with lenalidomide and dexamethasone until disease progression is therefore considered a standard therapy for second line treatment in multiple myeloma patients. However, only a relatively low rate of high quality response (CR, complete response and VGPR, very good partial response) is achieved. High quality responses are associated with with improved progression-free survival and overall survival [4].

Trial: The aim of this trial is to improve high quality response rates for patients with relapsed or refractory multiple myeloma in the 2nd line treatment. This aim shall be achieved by the addition a third anti-myeloma drug (bendamustine) to the established backbone of lenalidomide/ dexamethasone.

Treatment regimen:

  • Induction Treatment Phase: Cycles 1-6 Bendamustine 75mg/m2/d day 1 and 2, lenalidomide 25mg/d 1-21, dexamethasone 40mg / 20mg (for patients > 75years) d 1, 8, 15, 22.
  • Maintenance Treatment Phase: Cycles 7-18 lenalidomide 25mg/d 1-21, dexamethasone 40mg / 20mg (for patients > 75 years) d 1, 8, 15, 22.

Due to hematoxicity of bendamustine and lenalidomide, administration of pegfilgrastim is mandatory in the induction treatment phase (BRd-regimen)for all patients experiencing severe neutropenia.

The aim of this study is to achieve high quality response rates (CR, VGPR) of ≥ 40%. If this aim is achieved, the treatment of bendamustine in combination with the established lenalidomide/ dexamethasone regimen will be considered promising.

Besides efficacy, the safety of this three-drug regimen is evaluated in this trial.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Assessments for efficacy / response evaluation:

  • M-protein quantitation in serum and 24 h urine collection samples by serum- and urine protein electrophoresis
  • Quantitation of immunoglobulin levels by nephelometry
  • Serum and urine immunofixation
  • Free light chain concentrations and ratio in the serum
  • Plasma cell percentage in the bone marrow by conventional cytology and biopsy with immunohistochemistry
  • Radiologic assessments of the skeleton

Response criteria: Response will be assessed according to IMWG criteria

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
      • St. Gallen, Switzerland, 9000
        • Kantonsspital St. Gallen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Written informed consent
  • Patients with first relapsed or refractory multiple myeloma (including patients with relapse after high dose chemotherapy followed by autologous stem cell transplantation) who have received no more than one prior line of anti-myeloma treatment
  • Treatment with a lenalidomide/ dexamethasone-based 2nd-line regimen is indicated and intended

  • Measurable disease as defined by at least one of the following 3 measurements

    • serum monoclonal protein level ≥ 1 g/dl (≥ 10 g/l) or
    • urine M-protein level ≥ 200 mg/24hours or
    • serum FLC assay: Involved FLC level ≥ 10 mg/dl (≥ 100 mg/l) provided serum FLC ratio is abnormal
  • ECOG performance status 0, 1, or 2
  • Age ≥ 18 years
  • All previous cancer therapy (except corticosteroid therapy), including radiation, cytostatic therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study.
  • No prior treatment with a bendamustine-containing regimen allowed
  • Prior treatment with lenalidomide is allowed if the treatment is completed > 12 month prior to study entry and the patient responded to prior lenalidomide treatment

  • Adequate hematological values:

    • absolute neutrophil count ≥ 1.5 x 109/L
    • platelets ≥ 100 x 109/L
    • hemoglobin > 80 g/L, unless considered to be caused by the underlying hematologic malignancy, based on the investigator's clinical judgement

  • Adequate hepatic function:

    • total bilirubin < 1.2 mg/dL
    • AST (SGOT) ≤ 2.5 x ULN

  • Adequate renal function:

    o calculated creatinine clearance > 50 ml/min, according to the formula of Cockcroft-Gault

  • Disease free of prior malignancies for > 5 years unless the patient

    • has been treated with a curative intent and is considered to be in complete remission for ≥2 years prior to study enrolment

    • or has a curatively-treated

      • basal cell/ squamous cell carcinoma of the skin,
      • carcinoma "in situ"of the cervix,
      • ductal breast carcinoma in situ with complete surgical resection (i.e. negative margins),
      • medullary or papillary thyroid tumor
      • or low grade, early stage localized prostate cancer treated surgically with curative intent

Exclusion Criteria:

  • Pregnant or breast feeding females
  • Any prior use of bendamustine
  • Patients who are unable or unwillingly to undergo antithrombotic therapy
  • Any serious underlying medical condition (at the judgment of the investigator) which impairs the ability of the patient to participate in the trial (e.g. active autoimmune disease, uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric disorder)
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she would participate in the study or any condition significantly confounding the ability to interpret data from the study, based on the local investigator's judgement
  • Severe cardiovascular disease, including myocardial infarction within 6 months before study entry, New York Heart Association Class III or IV heart failure, uncontrolled angina or severe uncontrolled ventricular arrhythmias (≥ Lown 3)
  • Use of any other experimental drug or therapy/ treatment in a clinical trial within 30 days prior to trial entry
  • Known hypersensitivity to study drug(s) or hypersensitivity to any other component of the study drugs
  • Any concurrent antineoplastic therapy with chemotherapeutic agents or biologic agents or radiation therapy
  • Any major surgical procedure within 30 days prior to study therapy
  • Known chronic hepatitis B or C, known HIV infection
  • Jaundice or any other severe damage of the liver parenchyma
  • Any contraindication for the treatment with bendamustine, lenalidomide, dexamethasone and / or pegfilgrastim in accordance with the appropriate SmPCs
  • Any other concomitant drugs contraindicated for use with the study drugs according to the national health authorities

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Bendamustine
All patients are treated with bendamustine in combination with lenalidomide and dexamethasone for a maximum of 6 cycles.
Drug: Bendamustine

Induction treatment phase (cycle 1-6):

  • Bendamustine 75 mg/m2 i.v day 1 and 2
  • Lenalidomide 25 mg p.o. day 1-21
  • Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22
  • Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia

Maintenance treatment phase (cycles 7-18):

  • Lenalidomide 25 mg p.o. day 1-21
  • Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22
Other Names:
  • Lenalidomide
  • Dexamethasone
  • Pegfilgrastim

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Efficacy (combined CR-/VGPR-rate) achieved during the induction treatment phase or within four weeks after the last administration of six induction cycles of the BRd regimen
Time Frame: Every 4 weeks up to 7 months
Every 4 weeks up to 7 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective response rates (sCR, CR, VGPR, PR, MR)
Time Frame: Every 4 weeks up to 7 months
Every 4 weeks up to 7 months
Best response (sCR, CR, VGPR, PR, MR)
Time Frame: Every 4 weeks up to 36 months
Every 4 weeks up to 36 months
Time to progression (TTP)
Time Frame: Every 4 weeks up to 36 months
Every 4 weeks up to 36 months
Overall survival (OS)
Time Frame: Every 8 weeks up to 36 months
Every 8 weeks up to 36 months
Safety and tolerability
Time Frame: Every 4 weeks until 30 days after completion of study treatment
  • Type, frequency, severity, and relationship of adverse events to study therapy
  • According to NCI CTCAE v4.0
Every 4 weeks until 30 days after completion of study treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cantonal Hospital of St. Gallen

Collaborators

Celgene Corporation
Amgen
Mundipharma Medical Company
Mundipharma Research GmbH & Co KG

Investigators

  • Study Chair: Ulrich Mey, MD, Kantonsspital Graubünden

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2012

Primary Completion (Actual)

February 1, 2016

Study Completion (Actual)

February 1, 2016

Study Registration Dates

First Submitted

September 27, 2012

First Submitted That Met QC Criteria

October 3, 2012

First Posted (Estimate)

October 4, 2012

Study Record Updates

Last Update Posted (Estimate)

August 24, 2016

Last Update Submitted That Met QC Criteria

August 23, 2016

Last Verified

August 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CTU10.041/BRd
  • 2010-022253-42 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Myeloma

Clinical Trials on Bendamustine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe